Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
Hans-Christian Kolberg, MD, Marienhospital Bottrop, Bottrop, Germany, comments on the results of the NeoMono trial, a Phase II neoadjuvant randomized clinical trial in triple-negative breast cancer patients, highlighting the importance of PD-L1 as a biomarker for immune checkpoint inhibitor therapy. Dr Kolberg notes that despite the trial’s unique design and high PCR rates, particularly in the PD-L1 positive population, no treatment interaction was observed, but PD-L1 remains a strong signal as an important biomarker. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
